Delayed vs initial cytomegalovirus prophylaxis after kidney transplantation

被引:1
作者
Laub, Melissa R. [1 ]
Byrns, Jennifer [1 ]
Gommer, Jennifer [1 ]
Ellis, Matthew [2 ]
Harris, Matt [1 ]
机构
[1] Duke Univ Hosp, Dept Pharm, Durham, NC USA
[2] Duke Univ Hosp, Dept Med, Durham, NC USA
关键词
cytomegalovirus; kidney transplantation; valganciclovir; RECIPIENTS; INHIBITORS; IMMUNOSUPPRESSION; BELATACEPT; REGIMENS;
D O I
10.1111/ctr.13854
中图分类号
R61 [外科手术学];
学科分类号
摘要
It is recommended to start cytomegalovirus (CMV) prophylaxis within 10 days of solid organ transplant, if indicated. Our center underwent a cost-savings initiative to delay CMV prophylaxis initiation from postoperative day zero to postoperative day 7 or upon discharge, hypothesizing this would not affect clinical outcomes but could impact costs. The purpose of this retrospective study was to determine the effects of early vs delayed (72 hours after transplant) CMV prophylaxis in kidney and kidney/pancreas transplant recipients transplanted between June 2014 and January 2017. The primary endpoint was incidence of CMV infection within 1 year. Secondary endpoints included CMV disease, CMV testing, and valganciclovir cost during index hospitalization. A total of 173 patients (114 early, 59 delayed) were included. CMV infection occurred in 61% vs 54% in the early vs delayed group (P = .5). Excluding low-level DNAemia (QNAT < 200 IU/mL), infection occurred in 30% vs 22% in the early vs late group (P = .4). The median days to starting prophylaxis were 0 and 6 in the early and delayed group (P < .05), which led to a median cost savings of $497.00 per patient during index hospitalization (P < .05). Delaying prophylaxis initiation did not impact CMV outcomes in this cohort and decreased costs.
引用
收藏
页数:7
相关论文
共 17 条
  • [1] Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor-Based Immunosuppression? A Systematic Review and Meta-Analysis
    Andrassy, Joachim
    Hoffmann, Verena S.
    Rentsch, Markus
    Stangl, Manfred
    Habicht, Antje
    Meiser, Bruno
    Fischereder, Michael
    Jauch, Karl-Walter
    Guba, Markus
    [J]. TRANSPLANTATION, 2012, 94 (12) : 1208 - 1217
  • [2] Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988-2004
    Bate, Sheri Lewis
    Dollard, Sheila C.
    Cannon, Michael J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 50 (11) : 1439 - 1447
  • [3] Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment
    Beam, Elena
    Razonable, Raymund R.
    [J]. CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (06) : 633 - 641
  • [4] Bjorn N, 2012, TRANSPLANTATION, V93, P1075
  • [5] Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection
    Cannon, Michael J.
    Schmid, D. Scott
    Hyde, Terri B.
    [J]. REVIEWS IN MEDICAL VIROLOGY, 2010, 20 (04) : 202 - 213
  • [6] Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis
    Cervera, Carlos
    Cofan, Frederic
    Hernandez, Cristina
    Soy, Dolors
    Angeles Marcos, Maria
    Sanclemente, Gemma
    Bodro, Marta
    Moreno, Asuncion
    Diekmann, Fritz
    Campistol, Josep Maria
    Oppenheimer, Frederic
    [J]. TRANSPLANT INTERNATIONAL, 2016, 29 (11) : 1216 - 1225
  • [7] A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation
    de Graav, Gretchen N.
    Baan, Carla C.
    Clahsen-van Groningen, Marian C.
    Kraaijeveld, Rens
    Dieterich, Marjolein
    Verschoor, Wenda
    von der Thusen, Jan H.
    Roelen, Dave L.
    Cadogan, Monique
    van de Wetering, Jacqueline
    van Rosmalen, Joost
    Weimar, Wilem
    Hesselink, Dennis A.
    [J]. TRANSPLANTATION, 2017, 101 (10) : 2571 - 2581
  • [8] Reduced exposure to calcineurin inhibitors in renal transplantation
    Ekberg, Henrik
    Tedesco-Silva, Helio
    Demirbas, Alper
    Vitko, Stefan
    Nashan, Bjorn
    Guerkan, Alp
    Margreiter, Raimund
    Hugo, Christian
    Grinyo, Josep M.
    Frei, Ulrich
    Vanrenterghem, Yves
    Daloze, Pierre
    Halloran, Philip F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (25) : 2562 - 2575
  • [9] Alemtuzumab Induction in Renal Transplantation
    Hanaway, Michael J.
    Woodle, E. Steve
    Mulgaonkar, Shamkant
    Peddi, V. Ram
    Kaufman, Dixon B.
    First, M. Roy
    Croy, Richard
    Holman, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (20) : 1909 - 1919
  • [10] A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients
    Juan, R. San
    Yebra, M.
    Lumbreras, C.
    Lopez-Medrano, F.
    Lizasoain, M.
    Meneu, J. C.
    Delgado, J.
    Andres, A.
    Aguado, J. M.
    [J]. CLINICAL TRANSPLANTATION, 2009, 23 (05) : 666 - 671